Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2023-02-14 12:36 pm Purchase | 13G | IBERE PHARMACEUTICALS IBERU | GLAZER CAPITAL LLC | 1,331,102 9.650% | 1,331,102 (New Position) | View |
2023-02-14 08:14 am Sale | 13G | IBERE PHARMACEUTICALS IBERU | CITADEL ADVISORS LLC | 4,057 0.000% | -775,377 (-99.48%) | View |
2023-02-08 3:19 pm Purchase | 13G | IBERE PHARMACEUTICALS IBERU | Hudson Bay Capital Management LP | 716,613 5.190% | 716,613 (New Position) | View |
2023-02-08 2:09 pm Sale | 13G | IBERE PHARMACEUTICALS IBERU | Hartree Partners LP | 0 0.000% | -1,285,000 (Position Closed) | View |
2023-02-02 11:10 am Sale | 13G | IBERE PHARMACEUTICALS IBERU | Magnetar Financial LLC | 785,872 5.690% | -7,419 (-0.94%) | View |
2022-02-14 06:12 am Purchase | 13G | IBERE PHARMACEUTICALS IBERU | CITADEL ADVISORS LLC | 779,434 5.600% | 779,434 (New Position) | View |
2022-02-08 4:23 pm Purchase | 13G | IBERE PHARMACEUTICALS IBERU | PIPV Capital LLC | 3,450,000 20.000% | 3,450,000 (New Position) | View |
2022-01-14 1:43 pm Purchase | 13G | IBERE PHARMACEUTICALS IBERU | Magnetar Financial LLC | 793,291 5.750% | 793,291 (New Position) | View |
2021-09-27 2:36 pm Purchase | 13G | IBERE PHARMACEUTICALS IBERU | Hartree Partners LP | 1,285,000 9.300% | 1,285,000 (New Position) | View |
2021-03-12 4:02 pm Purchase | 13G | IBERE PHARMACEUTICALS IBERU | CITADEL ADVISORS LLC | 776,710 5.600% | 776,710 (New Position) | View |